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Src-like adaptor protein (Slap) is a negative regulator of
mitogenesis
Serge Roche*, Gema Alonso†, Andrius Kazlauskas‡, Vishva M. Dixit§, 
Sara A. Courtneidge¶ and Akhilesh Pandey§
The Src-like adaptor protein (Slap) is a recently
identified adaptor protein containing Src homology 3
(SH3) and SH2 domains. Slap is found in a wide range
of cell types and was shown to interact with the Eck
receptor tyrosine kinase in a yeast two-hybrid
interaction screen [1]. Here, we found that Slap is
expressed in NIH3T3 cells and could associate with the
activated platelet-derived growth factor (PDGF)
receptor. Using mutated versions of the PDGF receptor
and phosphopeptide competition experiments, we
determined that Slap has the highest affinity for the
Src-binding site of the PDGF receptor. Our inability to
produce cell lines that stably expressed Slap suggested
that Slap inhibited cell growth. We further investigated
this issue by transiently expressing Slap by
microinjection. Overexpression of Slap by this method
inhibited DNA synthesis induced by PDGF and serum,
whereas overexpression of the adaptor proteins Grb2
and Shc did not. Finally, microinjection of a Slap
antibody into NIH3T3 cells that had been stimulated
with suboptimal doses of growth factors potentiated
the effects of the growth factors. These data suggest
that, unlike other adaptor proteins, Slap is a negative
regulator of signalling initiated by growth factors.
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Results and discussion
We first asked whether Slap is expressed in fibroblasts and
whether it associates with the activated PDGF receptor. A
polyclonal antibody raised against the carboxyl terminus
of Slap recognised Slap in Cos7 cells that had been trans-
fected with an expression vector encoding a haemagglu-
tinin (HA) epitope-tagged version of Slap (Figure 1a). In
addition, this antibody specifically immunoprecipitated a
protein of the same size (34 kDa) from lysates of NIH3T3
fibroblasts, and the antibody also only recognised a single
Figure 1
Slap associates with the PDGF receptor.
(a) Characterisation of the anti-Slap antibody.
Slap was immunoprecipitated (IP) from Cos7
cells expressing HA–Slap, or NIH3T3 cells,
using preimmune serum (PI), anti-HA
antibody, or anti-Slap antibody as indicated,
and the immunoprecipitates were analysed by
SDS–PAGE and western blotting. The blots
were then probed with anti-HA or anti-Slap
antibody as shown. The ability of the anti-
Slap antibody to detect Slap in whole
NIH3T3 cell lysates was also tested (right).
Arrows mark the position of the Slap protein.
(b) Association of Slap with the activated
PDGF receptor. Slap and the PDGF receptor
were immunoprecipitated using the
antibodies indicated from quiescent NIH3T3
cells treated with or without PDGF. The
immunoprecipitated proteins were subjected
to SDS–PAGE and then visualised by
western blotting using antibodies against Slap
(anti-Slap), the PDGF receptor (anti-PDGFR)
or phosphotyrosine residues (anti-pTyr).
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band of 34 kDa when whole cell lysates were probed,
demonstrating its specificity for Slap (Figure 1a). In quies-
cent fibroblasts stimulated with PDGF, Slap was associ-
ated with the activated PDGF receptor, as revealed by
probing both PDGF receptor and Slap immunoprecipi-
tates with the appropriate antibodies (Figure 1b). As with
the adaptor molecules, Grb2 and Grb10 [2,3], the associa-
tion with the PDGF receptor did not, however, lead to
tyrosine phosphorylation of Slap itself.
The predominant site on the PDGF receptor to which c-
Src binds is tyrosine 579 (Y579), which is located in the
juxtamembrane region; the phosphorylated Y581 residue is
also involved in c-Src binding [4]. To determine whether
these or other phosphotyrosine residues were critical for
engaging Slap, HepG2 cells expressing various PDGF
receptor mutants [5] were analysed (Figure 2a). Slap could
still associate with a receptor in which five major tyrosine
phosphorylation sites — not including Y579 and Y581 —
had been mutated into phenylalanine residues (F5). Slap
also associated with the Y581F mutant, but with apparently
lower affinity than with the F5 mutant, suggesting that
Y579 might be the binding site for Slap. This could not be
tested directly, because of the reduced kinase activity of
PDGF receptor Y579F mutants [4].
Instead, a phosphopeptide competition approach was used
[6]. A glutathione-S-transferase (GST) fusion protein con-
taining the amino terminus and the SH3 and SH2 domains
of Slap — GST–Slap(N,SH3,SH2) — bound to the PDGF
receptor in vitro. Addition of a peptide corresponding to the
Src-binding site on the PDGF receptor, containing phos-
phorylated Y579 and Y581 residues, inhibited this binding
(Figure 2b). Peptides corresponding to binding sites for
phosphatidylinositol (PI) 3-kinase, ras GTPase-activating
protein (rasGAP) and phospholipase Cγ did not compete. A
peptide containing phosphorylated YEEI (pYEEI, the
general consensus binding sequence for c-Src [7]) also abol-
ished the binding of Slap to the PDGF receptor. These
data suggest that the Slap SH2 domain has a similar binding
specificity to the Src SH2 domain. To test this, Src was
immunoprecipitated from a cell lysate of Sf9 insect cells
infected with a Src-producing baculovirus, and incubated
with baculovirus-produced PDGF receptor protein, in the
presence or the absence of purified GST fusion proteins, as
indicated in Figure 2c. GST–Slap competed efficiently
with Src for PDGF receptor binding. GST alone, a Slap
construct deleted in the SH2 domain — GST–Slap(N,SH3)
— and a GST construct containing the SH2 and SH3
domains of rasGAP — GST–GAP(SH2,SH3,SH2) — did
not compete for binding, however. Furthermore, in other
experiments, we determined that the SH2 domains of Slap
and the Src family kinase Fyn bound to the PDGF receptor
in vitro with similar affinities (data not shown). Collectively,
these data suggest that Slap uses the same binding site(s)
on the PDGF receptor as c-Src, although we cannot rule out
that it might also associate with other phosphorylated tyro-
sine residues that were not tested here.
To investigate the effect of Slap overexpression, NIH3T3
cells were transfected with an expression vector encoding
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Figure 2
Slap and Src share a binding site on the PDGF receptor. (a) Slap
association with mutant PDGF receptors in vitro. HepG2 cells
expressing an empty expression vector (vector) or various PDGF
receptor mutants were metabolically labelled with 35S-
methionine/cysteine for 6 h, treated with PDGF (100 ng/ml) for 5 min
and then lysed. After incubation with GST–Slap(N,SH3,SH2), the PDGF
receptor was immunoprecipitated using anti-PDGF receptor (anti-
PDGFR) antibody, subjected to SDS–PAGE and visualised by
autoradiography. The various PDGF receptors tested were: wild type
(WT); the R635 kinase-deficient receptor mutant (R635); the F5 mutant,
which has five major tyrosine phosphorylation sites mutated to
phenylalanine; the F581 mutant, which carries the Y581 to phenylalanine
mutation; and the F5/581 mutant, which corresponds to the F5 mutant
with the additional Y581 to phenylalanine mutation. (b) Inhibition of
binding of Slap to the PDGF receptor by phosphotyrosine-containing
peptides. Immobilised GST–Slap(N,SH3,SH2) was incubated with
different peptides containing the indicated tyrosine residues
(phosphorylated and unphosphorylated) before a lysate of insect cells
expressing the human PDGF receptor was added. After washing, the
presence of the bound receptor was detected by an in vitro kinase assay
[6]. (c) Slap competes with Src for binding to the PDGF receptor in
vitro. Src was immunoprecipitated from baculovirus-infected Sf9 cells,
and incubated in vitro with baculovirus-produced PDGF receptor in the
presence and absence of purified GST fusion proteins as indicated. The
association of the PDGF receptor with Src was monitored by
immunoprecipitating Src with the anti-cst.1 antibody (which is raised
against the seven carboxy-terminal amino acids of Src) and then
immunoblotting with an anti-PDGF receptor antibody .
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FLAG-epitope-tagged Slap (Slap–FLAG), and subse-
quently selected for G418 resistance. Surprisingly, no
Slap-expressing colonies were obtained, although several
colonies (495 per µg DNA) were obtained with the empty
vector. Colonies were obtained when the adaptor proteins
Grb2 (484 per µg DNA) and Shc (450 per µg DNA) were
transfected. These observations suggest that, in contrast to
other adaptor proteins, overexpression of Slap was either
toxic or growth inhibitory for NIH3T3 fibroblasts. Tran-
sient expression by microinjection was used to investigate
this further [8,9]. Data from several experiments, when
pooled and analysed, indicated that overexpression of Slap
inhibited more than 90% of cells from entering S phase in
response to PDGF, when compared with control cells
(Figure 3). Microinjection of Shc and Grb2 did not inhibit
DNA synthesis. (Figure 3a). Slap inhibition required an
intact SH2 domain, but not the SH3 domain (Figure 3b).
This effect was specific for the SH2 domain of Slap
because a chimeric molecule in which the Slap SH2
domain was replaced by the amino-terminal SH2 domain
of Gap — Slap–GAP(SH2) — was also not inhibitory
(Figure 3b). Similar results were obtained when GST
fusions of Slap were microinjected into fibroblasts (data
not shown). Overexpression of Slap with an intact SH2
domain also inhibited the mitogenic response of cells to
serum (Figure 3c,d).
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Figure 3
Slap and Slap∆SH3 inhibit the mitogenic
response induced by both PDGF and serum,
whereas Shc, Grb2, Slap∆SH2 and
Slap–GAP(SH2) have no effect. Quiescent
NIH3T3 cells were microinjected with the
indicated constructs, stimulated with 
(a,b) PDGF or (c,d) foetal calf serum (FCS), in
the presence of bromodeoxyuridine (BrdU) for
18 h, labelled with an anti-BrdU antibody and
processed for immunofluorescence. Statistical
analysis of cells that incorporated BrdU as a
marker of DNA synthesis is represented on the
graph. Values shown are ± SD.
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Figure 4
Inhibition of Slap potentiates mitogenesis.
Quiescent NIH3T3 cells were microinjected
with an affinity-purified anti-Slap antiserum, or
anti-Slap antiserum preincubated with the
immunising peptide (pep), as indicated. Cells
were then stimulated with a suboptimal
concentration of (a) PDGF (5ng/ml) or 
(b) serum (2.5%) for 18 h, and DNA synthesis
was measured as described in the legend to
Figure 3. Values shown are ± SD.
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If inhibition of mitogen-induced DNA synthesis is the
physiological role of Slap, then removal of Slap should
potentiate signalling. To test this, cells were microin-
jected with the Slap antibody, and then stimulated with a
suboptimal dose of PDGF or serum. We observed that
more microinjected cells entered S phase than control
cells (Figure 4a,b). Preincubation of the antibody with the
immunising peptide demonstrated that these potentiation
effects were specific for Slap. We conclude that the
endogenous level of Slap in NIH3T3 cells can influence
whether the cells progress though the cell cycle in
response to a particular concentration of growth factor.
It is not clear how Slap inhibits the cell cycle. Preliminary
data indicate that Slap inhibition can be overcome by het-
erologous expression of Myc (S.R., unpublished observa-
tions) suggesting that Slap antagonises the Src pathway
[10]. Negative regulation of receptor-activated signalling
pathways may be a general theme in cell growth control.
Other recent examples include FRNK (FAK-related non-
kinase), the Cis family of proteins that regulate cytokine
signalling, and the T-cell adaptor protein Cbl [11–16].
Materials and methods
Slap and various mutants were derived by PCR, tagged with a FLAG
epitope, and then cloned into pcDNA3 (Invitrogen). Slap(GAPSH2)
contains the amino-terminal SH2 domain of GAP in place of the Slap
SH2 domain. Expression constructs encoding Myc-tagged Grb2 and
Shc were a gift from Ben Margolis (University of Michigan). Rabbit anti-
Slap serum against the nine carboxy-terminal residues of the mouse
Slap sequence was affinity-purified as described [9]. Fusion proteins
were purified as described [17]. Other antibodies, immunoprecipitation
techniques, kinase assays, and peptide and peptide competition
methodology have been described previously [6,18]. For microinjection
analysis, NIH3T3 cells were seeded, synchronised and microinjected
as described [19]. Plasmids (100 ng/ml) were injected into the nucleus
4–6 h before cell stimulation. Affinity-purified antibody (1–2 mg/ml)
was injected into the cytoplasm. Cells were stimulated for 18 h with
PDGF (25 ng/ml unless otherwise indicated) or FCS (10% unless oth-
erwise indicated), in medium containing BrdU (Sigma; 0.1 mM). BrdU
incorporation was measured as described [9]. For transfection,
NIH3T3 cells were seeded into 6-well dishes and transfected with 2 µg
DNA per well using lipofectamine (Gibco BRL) according to manufac-
turer’s instructions. The cells were trypsinised 24 h later and placed in
selection medium containing 0.4 mg/ml G418. After 2–3 weeks, the
number of colonies were visualised and counted by staining with
crystal violet. For PDGF receptor association assays, cell lysates made
from PDGF-treated or PDGF-untreated HepG2 cells expressing mutant
PDGF receptors [5] were incubated with GST–Slap(N,SH3,SH2) or
GST–Src(SH2) for 2 h at 4°C. Pelleted beads were then washed,
boiled in 1% SDS to elute the bound material, diluted to a final concen-
tration of 0.1% SDS, and immunoprecipitated using an antibody against
the PDGF receptor. Association of the PDGF receptor with Slap in
fibroblasts was assayed from lysates of quiescent fibroblasts that had
been stimulated with PDGF (50 ng/ml) for 5 min or left unstimulated.
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